ClinicalTrials.gg
TerminatedNCT03726333Updated Jun 21, 2024Results posted

Hepatic Impairment Study for Lorlatinib in Cancer Patients

A Phase 1 interventional study of lorlatinib and lorlatinib in Advanced Cancers, sponsored by Pfizer. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
The study stopped due to lack of enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase 1 study in advanced cancer patients with varied hepatic functions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.

Read the detailed description

This will be a Phase 1, open label, multi center, multiple dose, non randomized, Phase 1 clinical trial of lorlatinib in advanced cancer patients with varying degrees of hepatic impairment and necessary age , weight , and gender matched prospect normal hepatic function patients. This study is intended to evaluate the potential effect of hepatic impairments on the PK and safety of lorlatinib after daily administration of lorlatinib and to provide dosing recommendation for patients with varied degree of hepatic impairment if possible.

Patients in the study will be assigned to different groups (A1, normal liver function, control for group B; A2, normal liver function, control for group C; B, mild hepatic impairment; C, moderate hepatic impairment; D, severe hepatic impairment) according to their liver function. The enrollment of approximately 76 advanced cancer patients is anticipated in this study in order to have 8 PK-evaluable patients in each of Groups A1, A2, B and C, and 6 PK-evaluable patients in Group D for final statistical analysis. Evaluable patients are those who complete the planned PK sample collection on Cycle 2 Day 1 and have no lorlatinib dose modification until completion of Cycle 2 Day 1 PK evaluation. Patients who are not evaluable for PK will be replaced. Each patient will be treated with repeated oral once daily doses of lorlatinib in 21-day cycles until disease progression, patient refusal, or unacceptable toxicity occurs. The dose schedule may be modified as necessary for individual patients according to tolerability.

02

Conditions studied

  • Advanced Cancers

Keywords

  • hepatic impairment
  • lorlatinib
  • cancer
  • pharmacokinetic
  • Lung cancer
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 1 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed solid or lymphoma that is or unresectable, and for which standard curative or palliative measures do not exist, or are no longer effective;
  • Biliary obstruction with a biliary drain or stent;
  • Neurologically stable gliomas and ;
  • performance status of 0, 1, or 2;
  • adequate bone marrow function;
  • adequate pancreatic function;
  • adequate renal function;
  • female patients with negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • untreated esophageal varices; uncontrolled ascites;
  • episodes of hepatic encephalopathy within the last 4 weeks;
  • spinal cord compression; major surgery within 4 weeks prior to enrollment;
  • radiation therapy within 2 weeks prior to enrollment;
  • last anti-cancer treatment within 2 weeks prior to screening;
  • previous high-dose chemotherapy requiring stem cell rescue;
  • prior to irradiation to >25% of the bone marrow;
  • gastrointestinal abnormalities;
  • known prior or suspected to lorlatinib or lorlatinib tablet;
  • bacterial, fungal or viral infections for non-liver cancer patients;
  • clinically significant cardiovascular disease;
  • uncontrolled hypertension; acute pancreatitis with predisposing characteristics;
  • history of grade 3 or 4 interstitial fibrosis or interstitial lung disease;
  • active hemoelysis or evidence of biliary sepsis;
  • prior major gastrointestinal surgery;
  • concurrent use of known strong inhibitors, inducers and P-gp substrates with a narrow therapeutic index;
  • concurrent use of CYP3A substrates with narrow therapeutic indices;
  • prior treatment with lorlatinib; active bleeding disorder
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Active comparator
    Group A1 Normal hepatic function

    continued daily administration of lorlatinib in patients with normal hepatic function

    Drug: lorlatinib

  • Active comparator
    Group A2 Normal hepatic function

    continued daily administration of lorlatinib in patients with normal hepatic function

    Drug: lorlatinib

  • Experimental
    Group B mild hepatic impairment

    continued daily administration of lorlatinib in patients with mild hepatic impairment

    Drug: lorlatinib

  • Experimental
    Group C moderate hepatic impairment

    continued daily administration of lorlatinib in patients with moderate hepatic impairment

    Drug: lorlatinib

  • Experimental
    Group D severe hepatic impairment

    continued daily administration of lorlatinib in patients with severe hepatic impairment

    Drug: lorlatinib

Interventions

  • continued daily administration of 100 mg lorlatinib

  • continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards

  • continued daily administration of 100 mg QD lorlatinib

  • continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients

  • continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C

06

What researchers measure

Primary outcomes

  1. Area Under Plasma Lorlatinib Concentration-Time Curve From Time 0 to Dosing Interval of 24 Hours (AUC24) at Steady State On Cycle 2 Day 1

    AUC24 was defined as area under the plasma concentration time profile during 1 dosing interval (24 hours).

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  2. Observed Maximal Plasma Concentration (Cmax) at Steady State on Cycle 2 Day 1

    Cmax was defined as maximum plasma concentration and was observed directly from data.

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

Secondary outcomes

  1. Number Of Patients Experienced Treatment Emergent Adverse Event Assessed by Investigator

    An Adverse event (AE) was any untoward medical occurrence in a participant. A serious AE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or that was considered to be an important medical event. AEs were graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. The grades were defined as follows: Grade 0: no change from normal or reference range; Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE. The focus of AE summaries was on treatment-emergent AE (TEAE). An AE was considered TEAE if the event occurred during the on-treatment period.

    Time frame: From Screening (within 28 days prior to Cycle 1 Day 1) through and including at least 28 days after after the last lorlatinib dose. The duration is approximately 42 days.

  2. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a best overall confirmed response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 relative to the response-evaluable population.

    Time frame: Baseline up to approximately 1 year

  3. Duration of Response (DR)

    DR was measured from the date that an objective tumor response (CR or PR) was first documented (whichever occurred first) to date of objective tumor progression or death due to any cause, whichever occurred first.

    Time frame: Baseline up to approximately 1 year

  4. Lorlatinib Area Under Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) After Single Dose on Cycle 1 Day 1

    AUClast was defined as area under the plasma concentration time profile from time 0 to the time of the last quantifiable concentration (Clast)

    Time frame: Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  5. The Time of The Last Quantifiable Concentration (Tlast) of Lorlatinib After Single Dose on Cycle 1 Day 1

    Tlast was defined as the time of the last quantifiable concentration.

    Time frame: Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  6. The Time to Cmax (Tmax) of Lorlatinib After Single Dose on Cycle 1 Day 1

    Tmax was defined as time for Cmax.

    Time frame: Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  7. Observed Minimal Plasma Concentration (Cmin) at Steady State On Cycle 2 Day 1

    Cmin was defined as minimum plasma concentration and was observed directly from data.

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  8. Plasma Lorlatinib AUClast at Steady State On Cycle 2 Day 1

    AUClast was defined as area under the plasma concentration time profile from time 0 to the time of Clast.

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  9. Plasma Lorlatinib Tlast at Steady State On Cycle 2 Day 1

    Tlast was defined as the time of the last quantifiable concentration.

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  10. Apparent Clearance (CL/F) at Steady State On Cycle 2 Day 1

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as Dose/AUC24 at steady-state.

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  11. Plasma Lorlatinib Metabolite AUC24 at Steady State

    AUC24 was defined as area under the plasma concentration time profile during one dosing interval (24 hours).

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  12. Plasma Lorlatinib Metabolite AUClast After Single Dose

    AUClast was defined as area under the plasma concentration time profile from time 0 to the time of Clast.

    Time frame: Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  13. Plasma Lorlatinib Metabolite AUClast at Steady State

    AUClast was defined as area under the plasma concentration time profile from time 0 to the time of Clast.

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  14. Plasma Lorlatinib Metabolite Cmax After Single Dose

    Cmax was defined as maximum plasma concentration and was observed directly from data.

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  15. Plasma Lorlatinib Metabolite Cmax at Steady State

    Cmax was defined as maximum plasma concentration and was observed directly from data.

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  16. Plasma Lorlatinib Metabolite Tlast After Single Dose

    Tlast was defined as the time of the last quantifiable concentration.

    Time frame: Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  17. Plasma Lorlatinib Metabolite Tlast at Steady State

    Tlast was defined as the time of the last quantifiable concentration.

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  18. Metabolite Ratio of Lorlatinib Metabolite for AUC24 (MRAUC24) at Steady State on Cycle 2 Day 1

    MRAUC24 was defined as metabolite ratio of lorlatinib metabolite for AUC24.

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  19. Metabolite Ratio of Lorlatinib Metabolite for AUClast (MRAUClast) at Steady State on Cycle 2 Day 1

    MRAUClast was defined as metabolite ratio of lorlatinib metabolite for AUClast.

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  20. Metabolite Ratio of Lorlatinib Metabolite for Cmax (MRCmax) at Steady State on Cycle 2 Day 1

    MRCmax was defined as metabolite ratio of lorlatinib metabolite for AUClast.

    Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

  21. Metabolite Ratio of Lorlatinib Metabolite for AUClast (MRAUClast) at Steady State on Cycle 1 Day 1

    MRAUClast was defined as metabolite ratio of lorlatinib metabolite for AUClast.

    Time frame: Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.

07

Results

Posted Jun 21, 2024
Limitations and caveats
The study was terminated due to difficulties with enrolling eligible patients. Only 1 participant was enrolled in this study. Outcome measures and AE data were not reported as planned in the protocol because doing so would risk re-dentification of the individual participant.

Participant flow

Participant flow — Overall Study
MilestoneGroup A1 Normal Hepatic FunctionGroup A2 Normal Hepatic FunctionGroup B Mild Hepatic ImpairmentGroup C Moderate Hepatic ImpairmentGroup D Severe Hepatic Impairment
Started00100
Completed00000
Not completed00100
Withdrew: Progressive disease00100

Outcome measures

PrimaryArea Under Plasma Lorlatinib Concentration-Time Curve From Time 0 to Dosing Interval of 24 Hours (AUC24) at Steady State On Cycle 2 Day 1

AUC24 was defined as area under the plasma concentration time profile during 1 dosing interval (24 hours).

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under Plasma Lorlatinib Concentration-Time Curve From Time 0 to Dosing Interval of 24 Hours (AUC24) at Steady State On Cycle 2 Day 1
nanogram*hour per milliliter (ng*hr/mL)Group B Mild Hepatic Impairment
Area Under Plasma Lorlatinib Concentration-Time Curve From Time 0 to Dosing Interval of 24 Hours (AUC24) at Steady State On Cycle 2 Day 1NA ± NA
PrimaryObserved Maximal Plasma Concentration (Cmax) at Steady State on Cycle 2 Day 1

Cmax was defined as maximum plasma concentration and was observed directly from data.

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Observed Maximal Plasma Concentration (Cmax) at Steady State on Cycle 2 Day 1
nanogram per milliliter (ng/mL)Group B Mild Hepatic Impairment
Observed Maximal Plasma Concentration (Cmax) at Steady State on Cycle 2 Day 1NA ± NA
SecondaryNumber Of Patients Experienced Treatment Emergent Adverse Event Assessed by Investigator

An Adverse event (AE) was any untoward medical occurrence in a participant. A serious AE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or that was considered to be an important medical event. AEs were graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. The grades were defined as follows: Grade 0: no change from normal or reference range; Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE. The focus of AE summaries was on treatment-emergent AE (TEAE). An AE was considered TEAE if the event occurred during the on-treatment period.

Time frame:
From Screening (within 28 days prior to Cycle 1 Day 1) through and including at least 28 days after after the last lorlatinib dose. The duration is approximately 42 days.
Reported as:
Count of participants · Participants
Number Of Patients Experienced Treatment Emergent Adverse Event Assessed by Investigator
ParticipantsGroup B Mild Hepatic Impairment
All-causality TEAEsNA
Treatment-related TEAEsNA
All-causality serious AEsNA
Treatment-related serious AEsNA
All-causalities AEs ≥Grade 3NA
Treatment-related AEs ≥Grade 3NA
All-causalities Grade 1 AEsNA
Treatment-related Grade 1 AEsNA
All-causalities Grade 2 AEsNA
Treatment-related Grade 2 AEsNA
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with a best overall confirmed response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 relative to the response-evaluable population.

Time frame:
Baseline up to approximately 1 year
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsGroup B Mild Hepatic Impairment
Objective Response Rate (ORR)0 (0 to 97.5)
SecondaryDuration of Response (DR)

DR was measured from the date that an objective tumor response (CR or PR) was first documented (whichever occurred first) to date of objective tumor progression or death due to any cause, whichever occurred first.

Time frame:
Baseline up to approximately 1 year
Reported as:
Median · Months
Duration of Response (DR)
MonthsGroup B Mild Hepatic Impairment
Duration of Response (DR)NA (NA to NA)
SecondaryLorlatinib Area Under Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) After Single Dose on Cycle 1 Day 1

AUClast was defined as area under the plasma concentration time profile from time 0 to the time of the last quantifiable concentration (Clast)

Time frame:
Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · ng*hr/mL
Lorlatinib Area Under Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) After Single Dose on Cycle 1 Day 1
ng*hr/mLGroup B Mild Hepatic Impairment
Lorlatinib Area Under Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) After Single Dose on Cycle 1 Day 1NA ± NA
SecondaryThe Time of The Last Quantifiable Concentration (Tlast) of Lorlatinib After Single Dose on Cycle 1 Day 1

Tlast was defined as the time of the last quantifiable concentration.

Time frame:
Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Median · hour
The Time of The Last Quantifiable Concentration (Tlast) of Lorlatinib After Single Dose on Cycle 1 Day 1
hourGroup B Mild Hepatic Impairment
The Time of The Last Quantifiable Concentration (Tlast) of Lorlatinib After Single Dose on Cycle 1 Day 1NA (NA to NA)
SecondaryThe Time to Cmax (Tmax) of Lorlatinib After Single Dose on Cycle 1 Day 1

Tmax was defined as time for Cmax.

Time frame:
Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Median · hour
The Time to Cmax (Tmax) of Lorlatinib After Single Dose on Cycle 1 Day 1
hourGroup B Mild Hepatic Impairment
The Time to Cmax (Tmax) of Lorlatinib After Single Dose on Cycle 1 Day 1NA (NA to NA)
SecondaryObserved Minimal Plasma Concentration (Cmin) at Steady State On Cycle 2 Day 1

Cmin was defined as minimum plasma concentration and was observed directly from data.

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · ng/mL
Observed Minimal Plasma Concentration (Cmin) at Steady State On Cycle 2 Day 1
ng/mLGroup B Mild Hepatic Impairment
Observed Minimal Plasma Concentration (Cmin) at Steady State On Cycle 2 Day 1NA ± NA
SecondaryPlasma Lorlatinib AUClast at Steady State On Cycle 2 Day 1

AUClast was defined as area under the plasma concentration time profile from time 0 to the time of Clast.

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · ng*hr/mL
Plasma Lorlatinib AUClast at Steady State On Cycle 2 Day 1
ng*hr/mLGroup B Mild Hepatic Impairment
Plasma Lorlatinib AUClast at Steady State On Cycle 2 Day 1NA ± NA
SecondaryPlasma Lorlatinib Tlast at Steady State On Cycle 2 Day 1

Tlast was defined as the time of the last quantifiable concentration.

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Median · hour
Plasma Lorlatinib Tlast at Steady State On Cycle 2 Day 1
hourGroup B Mild Hepatic Impairment
Plasma Lorlatinib Tlast at Steady State On Cycle 2 Day 1NA (NA to NA)
SecondaryApparent Clearance (CL/F) at Steady State On Cycle 2 Day 1

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as Dose/AUC24 at steady-state.

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · Liter per hour (L/hr)
Apparent Clearance (CL/F) at Steady State On Cycle 2 Day 1
Liter per hour (L/hr)Group B Mild Hepatic Impairment
Apparent Clearance (CL/F) at Steady State On Cycle 2 Day 1NA ± NA
SecondaryPlasma Lorlatinib Metabolite AUC24 at Steady State

AUC24 was defined as area under the plasma concentration time profile during one dosing interval (24 hours).

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · ng*hr/mL
Plasma Lorlatinib Metabolite AUC24 at Steady State
ng*hr/mLGroup B Mild Hepatic Impairment
Plasma Lorlatinib Metabolite AUC24 at Steady StateNA ± NA
SecondaryPlasma Lorlatinib Metabolite AUClast After Single Dose

AUClast was defined as area under the plasma concentration time profile from time 0 to the time of Clast.

Time frame:
Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · ng*hr/mL
Plasma Lorlatinib Metabolite AUClast After Single Dose
ng*hr/mLGroup B Mild Hepatic Impairment
Plasma Lorlatinib Metabolite AUClast After Single DoseNA ± NA
SecondaryPlasma Lorlatinib Metabolite AUClast at Steady State

AUClast was defined as area under the plasma concentration time profile from time 0 to the time of Clast.

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · ng*hr/mL
Plasma Lorlatinib Metabolite AUClast at Steady State
ng*hr/mLGroup B Mild Hepatic Impairment
Plasma Lorlatinib Metabolite AUClast at Steady StateNA ± NA
SecondaryPlasma Lorlatinib Metabolite Cmax After Single Dose

Cmax was defined as maximum plasma concentration and was observed directly from data.

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · ng/mL
Plasma Lorlatinib Metabolite Cmax After Single Dose
ng/mLGroup B Mild Hepatic Impairment
Plasma Lorlatinib Metabolite Cmax After Single DoseNA ± NA
SecondaryPlasma Lorlatinib Metabolite Cmax at Steady State

Cmax was defined as maximum plasma concentration and was observed directly from data.

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · ng/mL
Plasma Lorlatinib Metabolite Cmax at Steady State
ng/mLGroup B Mild Hepatic Impairment
Plasma Lorlatinib Metabolite Cmax at Steady StateNA ± NA
SecondaryPlasma Lorlatinib Metabolite Tlast After Single Dose

Tlast was defined as the time of the last quantifiable concentration.

Time frame:
Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Median · hour
Plasma Lorlatinib Metabolite Tlast After Single Dose
hourGroup B Mild Hepatic Impairment
Plasma Lorlatinib Metabolite Tlast After Single DoseNA (NA to NA)
SecondaryPlasma Lorlatinib Metabolite Tlast at Steady State

Tlast was defined as the time of the last quantifiable concentration.

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Median · hour
Plasma Lorlatinib Metabolite Tlast at Steady State
hourGroup B Mild Hepatic Impairment
Plasma Lorlatinib Metabolite Tlast at Steady StateNA (NA to NA)
SecondaryMetabolite Ratio of Lorlatinib Metabolite for AUC24 (MRAUC24) at Steady State on Cycle 2 Day 1

MRAUC24 was defined as metabolite ratio of lorlatinib metabolite for AUC24.

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · Ratio
Metabolite Ratio of Lorlatinib Metabolite for AUC24 (MRAUC24) at Steady State on Cycle 2 Day 1
RatioGroup B Mild Hepatic Impairment
Metabolite Ratio of Lorlatinib Metabolite for AUC24 (MRAUC24) at Steady State on Cycle 2 Day 1NA ± NA
SecondaryMetabolite Ratio of Lorlatinib Metabolite for AUClast (MRAUClast) at Steady State on Cycle 2 Day 1

MRAUClast was defined as metabolite ratio of lorlatinib metabolite for AUClast.

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · Ratio
Metabolite Ratio of Lorlatinib Metabolite for AUClast (MRAUClast) at Steady State on Cycle 2 Day 1
RatioGroup B Mild Hepatic Impairment
Metabolite Ratio of Lorlatinib Metabolite for AUClast (MRAUClast) at Steady State on Cycle 2 Day 1NA ± NA
SecondaryMetabolite Ratio of Lorlatinib Metabolite for Cmax (MRCmax) at Steady State on Cycle 2 Day 1

MRCmax was defined as metabolite ratio of lorlatinib metabolite for AUClast.

Time frame:
Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · Ratio
Metabolite Ratio of Lorlatinib Metabolite for Cmax (MRCmax) at Steady State on Cycle 2 Day 1
RatioGroup B Mild Hepatic Impairment
Metabolite Ratio of Lorlatinib Metabolite for Cmax (MRCmax) at Steady State on Cycle 2 Day 1NA ± NA
SecondaryMetabolite Ratio of Lorlatinib Metabolite for AUClast (MRAUClast) at Steady State on Cycle 1 Day 1

MRAUClast was defined as metabolite ratio of lorlatinib metabolite for AUClast.

Time frame:
Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Reported as:
Geometric mean · Ratio
Metabolite Ratio of Lorlatinib Metabolite for AUClast (MRAUClast) at Steady State on Cycle 1 Day 1
RatioGroup B Mild Hepatic Impairment
Metabolite Ratio of Lorlatinib Metabolite for AUClast (MRAUClast) at Steady State on Cycle 1 Day 1NA ± NA

Adverse events

Collected over From Screening (within 28 days prior to Cycle 1 Day 1) through and including at least 28 days after after the last lorlatinib dose. The duration is approximately 42 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group B Mild Hepatic Impairment0/1 (0%)1/1 (100%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventGroup B Mild Hepatic Impairment
Nervous system disordersNervous system disorders1/1
Psychiatric disordersPsychiatric disorders1/1
Most frequent other events
Most frequent other events
EventGroup B Mild Hepatic Impairment
General disordersGeneral disorders1/1
Metabolism and nutrition disordersMetabolism and nutrition disorders1/1
Nervous system disordersNervous system disorders1/1
Psychiatric disordersPsychiatric disorders1/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Group B Mild Hepatic Impairment
<=18 yearsNA
Between 18 and 65 yearsNA
>=65 yearsNA
Sex: Female, Male
Sex: Female, Male(Participants)Group B Mild Hepatic Impairment
FemaleNA
MaleNA
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group B Mild Hepatic Impairment
Hispanic or LatinoNA
Not Hispanic or LatinoNA
Unknown or Not ReportedNA
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group B Mild Hepatic Impairment
American Indian or Alaska NativeNA
AsianNA
Native Hawaiian or Other Pacific IslanderNA
Black or African AmericanNA
WhiteNA
More than one raceNA
Unknown or Not ReportedNA
08

Study locations

10 sites
  • University of Colorado Denver CTO (CTRC)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital, Anschutz Cancer Pavilion (ACP)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital, Anschutz Inpatient Pavilion (AIP)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital, Anschutz Outpatient Pavilion (AOP)
    Aurora, Colorado 80045, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Investigational Drug Service
    Atlanta, Georgia 30322, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
  • Mays Cancer Center
    San Antonio, Texas 78229, United States
  • University Health System
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Jul 2021, 17 months.

Results were first posted in Jun 2024, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2018
First posted
Oct 31, 2018
StartActual
Jan 14, 2020
Primary completionActual
Jul 8, 2021
CompletionActual
Jul 8, 2021
Results first posted
Jun 21, 2024
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03726333
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 31, 2018
Start date
Jan 14, 2020
Primary completion
Jul 8, 2021
Completion
Jul 8, 2021
Results posted
Jun 21, 2024
Last update
Jun 21, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorlatinib

Start the discussion